Indirect Hyperbilirubinemia (Neonatal jaundice). Neonatal jaundice due to excessive hemolysis, unspecified
Conditions
Interventions
Intervention 1: First intervention group: Patients in this group are treated with Ursodoxicillic acid (Alborzdarou Pharmaceutical Company) 10 mg/kg daily with phototherapy for two days. Intervention 2
Sponsors
Sabzevar University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Days to 14 Days
Inclusion criteria
Inclusion criteria: Infants aged 2 to 14 days. Infants with a serum bilirubin level between 14 and 25 mg/dl and direct bilirubin of less than 2 mg/dl. Infants with reticulocyte count in normal range. Infants with no Hematoma cerebral and Caput succedaneum. Infants with gestational age greater than 37 weeks. Infants with birth weight more than 2500 grams. Infants without polycythemia (hematocrit over 65). Infants without underlying illness. Infants without exchange transfusion.
Exclusion criteria
Exclusion criteria: Infants with low hemoglobin and positive glucose 6-phosphate dehydrogenase enzyme and Coombs tests. Infants who receive serum therapy, antibiotic therapy, and IV immunoglobulin (IVIG). Infants with abnormal peripheral blood smear tests. Infants with septicemia, Crigler–Najjar syndrome, thyroid and liver diseases. Infants from diabetic mother. Infants with direct hyperbilirubinemia, blood type incompatibility, and RH.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total bilirubin. Timepoint: At the beginning of the study (before the intervention), 12, 24 and 48 hours after starting the intervention. Method of measurement: Flame photometry device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Dr. Mitra Aldaghi
Sabzevar University of Medical Sciences
Outcome results
None listed